5 Best Dow Dividend Stocks To Own Right Now

The 10 Highest Capital Gains Tax States

A lot of small business owners accelerated sales of their companies into 2012 in anticipation of the new higher tax rates for 2013, but for those who are thinking of selling now, don�� despair.

��here are things you can do to minimize��r with the right set of facts��liminate taxes,��says Timothy Jessell, a tax lawyer with Greenberg Traurig in Tysons Corner, Va. whose client base is people buying and selling companies. In one case, a client who is selling his consulting company will save $3.8 million in taxes ��imply by filing a piece of paper,��he says.

What�� the tax picture if you��e selling a business? The American Taxpayer Relief Act lifted the top rate on long-term capital gains from 15% to 20% and allowed the return of a gotcha provision that adds another 1.2% to the tax bite as of Jan. 1. Plus, a new 3.8% Medicare surtax (one of the Obamacare taxes) on investment income for couples earning more than $250,000 kicked in��aising the total top capital gains rate from 15% to 25%.

5 Best Blue Chip Stocks To Own For 2015: Senomyx Inc.(SNMX)

Senomyx, Inc. engages in the discovery and development of novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas using proprietary taste receptor-based assays and screening technologies. The company has product discovery, development, and commercialization collaborations with seven food, beverage, and ingredient companies, including Ajinomoto Co., Inc.; Firmenich SA; Kraft Foods, Inc.; Nestle SA; and PepsiCo, Inc. Senomyx, Inc. licenses flavor ingredients to its collaborators on an exclusive or co-exclusive basis. The company was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Healthcare stocks gained Wednesday, with Senomyx (NASDAQ: SNMX) leading advancers after the company announced a research agreement with PepsiCo (NYSE: PEP). Among the leading sector stocks, gains came from Pernix Therapeutics Holdings (NASDAQ: PTX), Albany Molecular Research (NASDAQ: AMRI) and Gentiva Health Services (NASDAQ: GTIV).

5 Best Dow Dividend Stocks To Own Right Now: MCG Capital Corporation(MCGC)

MCG Capital Corporation is a private equity firm specializing in investments in middle market companies. The firm does not prefer investments in highly cyclical and volatile industry sectors and businesses with significant volatility exposure. It seeks to invest in small to mid sized companies. The firm prefers to invest in acquisitions, growth financings, organic growth, recapitalization, and leveraged buyouts. It invests in companies based in the United States. The firm seeks to invest upto $75 million in debt and equity in companies having revenues between $20 million and $200 million and EBITDA between $3 million and $25 million. It seeks to invest in the form of senior debt, including amortizing, bullet maturity, term loans, and revolving credit facilities; institutional sub debt, including junior capital; second lien debt, that includes term loans on sole source and participant basis; secured and unsecured subordinate loans structured as current interest, deferred in terest, and equity linked components; mezzanine debt and equity that includes minority equity investments. The firm may invest in minority or control equity positions. It was formerly known as MCG Credit Corporation. MCG Capital Corporation was founded in 1990 and is based in Arlington, Virginia.

Advisors' Opinion:

• [By Equities Lab]

  The stocks that currently pass the stock screen in order of market cap are Frontier Communications Corp , Crown Media Holdings (CRWN), Vonage Holding (VG), MCG Capital Corp (MCGC), 1-800-FLOWERS.COM (FLWS), MTR Gaming Corporation (MNTG), Alaska Communications (ALSK), and Enzon Pharmaceuticals (ENZN).

5 Best Dow Dividend Stocks To Own Right Now: Opko Health Inc(OPK)

OPKO Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It provides a range of solutions, including molecular diagnostics tests, proprietary pharmaceuticals, and vaccines to diagnose, treat, and prevent neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company offers molecular diagnostic platform technology for the rapid identification of molecules or immunobiomarkers; Alzheimer?s test for Alzheimer?s diagnostic; and protein-based influenza vaccines to provide multi-season and multi-strain protection against various influenza virus strains, such as seasonal influenza strains, as well as global influenza pandemic strains which include swine flu, and avian flu. It also offers Oligonucleotide Therapeutics for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and oligosaccharide for asthma and chronic obstructive pulmonary diseases. In addition, the company provides Rolapitant, a potent and antagonist; neurokinin-1, which has completed Phase II clinical trials for prevention of chemotherapy induced nausea and vomiting, and post-operative induced nausea and vomiting; and SCH 900978 that has completed Phase II clinical trials for chronic cough. Further, it offers bevasiranib, a drug candidate for the treatment of Wet AMD; and develops Aquashunt, a shunt to be used in the treatment of glaucoma. Additionally, the company involves in the development, commercialization, and sale of ophthalmic diagnostic and imaging systems, and instrumentation products. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Advisors' Opinion:

• [By James E. Brumley]

  Look out Roche Holding Ltd. (OTCMKTS:RHHBY), and Opko Health Inc. (NYSE:OPK) - you're on notice too. There's a new player in the human growth hormone arena, and it may have built the proverbial better mousetrap. Versartis Inc. (NASDAQ:VSAR) only went public in late March, but with the dust from that IPO settling, it's already becoming clear that VSAR - admittedly a one-trick pony - could pose a real threat to OPK and RHHBY... at least on the human growth hormone front.

5 Best Dow Dividend Stocks To Own Right Now: Stereotaxis Inc.(STXS)

Stereotaxis, Inc. designs, manufactures, and markets cardiology instrument control systems for use in a hospital?s interventional surgical suite or interventional lab for the treatment of arrhythmias and coronary artery diseases in the United States and internationally. The company provides Niobe system, which includes Niobe Magnetic Navigation System that navigates catheters, guidewires, and other delivery devices through complex paths in the blood vessels and chambers of the heart to carry out treatment; Navigant, a user interface or physician control center, which physicians use to visualize and track procedures and to provide instrument control commands that govern the motion of the working tip of the catheter, guidewire, or other interventional device; Cardiodrive, a catheter advancement system to remotely advance and retract the catheter in the patient?s heart. It also offers Odyssey enterprise solutions, which provides information solutions to manage, control, rec ord, and share procedures across networks; acquires remote view of the lab capturing synchronized procedure data for review of important events during cases; and review recorded cases and create snapshots following procedures for clinical reporting, auditing, and presentation. In addition, the company provides disposable interventional devices comprising automated catheters, coronary guidewires, and navigation and ablation systems. It markets its products through its direct sales force, distributors, and sales agents. The company was founded in 1990 and is headquartered in St. Louis, Missouri.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 health care player that looks poised for a potentially large move higher is Stereotaxis (STXS), which designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. This stock has been on fire so far in 2013, with shares up big by 43%.

  If you take a look at the chart for Stereotaxis, you'll notice that this stock has formed a major bottom pattern over the last three months, since this stock has found buying interest each time it has pulled back towards $3.50 and $3.10 a share. Buyers have stepped in at those levels and have not let the sellers pressure STXS lower. Shares of STXS are now starting to spike higher today right off its 50-day moving average of $3.59 a share. That spike is quickly pushing shares of STXS within range of triggering a big breakout trade above a key downtrend line.

  Traders should now look for long-biased trades in STXS if it manages to break out above some near-term overhead resistance at $4 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.98 million shares. If that breakout triggers soon, then STXS will set up to re-test or possibly take out its next major overhead resistance levels at $5 to $6.24 a share. Any high-volume move above $6.24 a share will then give STXS a chance to re-fill some of its previous gap down zone from August that started at $10 a share.

  Traders can look to buy STXS off any weakness to anticipate that breakout and simply use a stop that sits right below those key support levels at $3.50 to $3.10 a share. One can also buy STXS off strength once it clears $4 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Bryan Murphy]

  Look out Intuitive Surgical, Inc. (NASDAQ:ISRG), and step aside BioTelemetry Inc. (NASDAQ:BEAT). There's a new cardiac name in town, and its name is Stereotaxis Inc. (NASDAQ:STXS). This small company's stock is soaring today on the heels of encouraging news, though the prompt for the stock's strength has been brewing for quite some time. This nudge for STXS, however, may well mean it has a lot more potential than ISRG or BEAT do for the foreseeable future.